Chicago-based Boundless Bio, Inc. (NASDAQ:BOLD) has seen significant insider reporting activity tied to its ten percent owner, Kristina Burow. According to a Form 4 filing submitted to the Securities and Exchange Commission, Burow sold shares of the company's common stock totaling $39,840 on July 1, 2026. This transaction was not a straightforward market sale but rather the result of a cashless stock option exercise.
During this exercise, Burow acquired 16,000 shares of Boundless Bio common stock at a price of $1.03 per share, creating a total acquisition value of $16,480. Simultaneously, she disposed of the identical 16,000 shares at a price of $2.49 per share. The net proceeds generated from this exercise were directed to ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., and ARCH Venture Fund X, L.P. The stock option itself was granted to Burow in her capacity as a member of the issuer's board of directors and had fully vested by June 15, 2026.
The sale price of $2.49 reflects the stock's recent performance trajectory. Over the past year, the shares have delivered a 134% return, while the last six months saw a 103% gain. According to InvestingPro analysis, the stock appears undervalued at current levels, trading below its Fair Value. The platform reveals 14 additional ProTips for BOLD investors, including insights on the company's cash position and profitability outlook.
The filing also listed Keith Crandell, Robert Nelsen, Steven Gillis, and Clinton Bybee as reporting owners. These individuals are associated with the ARCH Venture Funds through their roles as managing directors or members of investment committees. They are reporting the transaction due to their indirect beneficial ownership of the shares held by these funds. They disclaim beneficial ownership except to the extent of any pecuniary interest.
Boundless Bio is currently navigating a major corporate transition. The company announced a definitive merger agreement with Serapha Bio, a clinical-stage biotechnology company. This all-stock transaction will result in the merged entity operating under the Serapha Bio name and trading on Nasdaq. Pre-merger Boundless Bio stockholders are expected to own approximately 3.7% of the combined company, while Serapha stockholders will own about 96.3%. Boundless Bio plans to declare a cash dividend of approximately $44 to $48 million to its pre-merger stockholders before the merger closes.
Operational adjustments are also underway. Boundless Bio agreed to terminate its San Diego lease, resulting in a $10 million payment to the landlord. Leadership changes were also noted during the company's annual meeting of stockholders, where James Christensen and Jennifer Lew were elected as Class II directors. Furthermore, the company presented preclinical data on its lead therapy, BBI-940, at a recent cancer research meeting.
This Form 4 is one of two reports filed jointly by the involved ARCH entities and individuals related to the same transaction. The reporting structure highlights the complex ownership dynamics between individual board members, venture capital funds, and the underlying publicly traded entity.